Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Antiviral prophylaxis can prevent the risk of biologic agents-associated HBV reactivation in
hepatitis B inactive carriers and patients with past HBV infection